Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Fluorescence Assays Global Market Report 2026

The clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market size has grown rapidly in recent years. It will grow from $1.57 billion in 2025 to $1.87 billion in 2026 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to rising demand for rapid molecular diagnostics, adoption of cas9-based detection tools, growth of academic and research institutes, expansion of pharmaceutical and biotechnology research, increasing prevalence of genetic research initiatives.

The clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market size is expected to see rapid growth in the next few years. It will grow to $3.83 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to growing adoption of multiplex and high-throughput assays, increasing integration with ai-enabled analysis platforms, rising demand for point-of-care diagnostics, expansion of clinical laboratory capabilities, increasing focus on personalized medicine applications. Major trends in the forecast period include increasing adoption of multiplex crispr fluorescence assays, rising demand for cas12 and cas13-based detection technologies, growing integration of real-time fluorescence readers, expansion of diagnostic and drug discovery applications, rising focus on high-sensitivity pathogen and biomarker detection.

The increasing preference for personalized medicine is anticipated to drive the growth of the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market in the coming years. Personalized medicine involves customizing medical treatment and preventive strategies according to an individual’s genetic makeup, environmental factors, and lifestyle characteristics to achieve maximum effectiveness. The expansion of personalized medicine is fueled by the growing incidence of chronic diseases, which demand targeted therapies that deliver better outcomes for individual patients compared to conventional treatments. CRISPR fluorescence assays support personalized medicine by facilitating rapid and highly specific identification of genetic mutations or biomarkers within a patient’s DNA, enabling physicians to detect disease-causing variants and customize treatments based on the patient’s unique genetic profile. For example, in February 2024, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for rare disease patients in 2023, an increase from six approvals in 2022. Consequently, the growing preference for personalized medicine is contributing to the expansion of the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market.

The increasing research and development activities are projected to accelerate the growth of the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market in the future. Research and development (R&D) activities encompass the creation and evaluation of new knowledge, products, or processes aimed at fostering innovation and business advancement. These activities are expanding as companies strive to achieve growth and maintain a competitive edge through the development of new and enhanced products or technologies. Research and development initiatives bolster CRISPR fluorescence assays by enhancing assay technologies, refining detection accuracy, and developing innovative solutions for genetic analysis and targeted therapeutic applications. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net expenditure on research and development (R&D) rose to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, representing an 8.2% increase. Therefore, the growing emphasis on research and development activities is driving the growth of the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market.

In December 2024, OraSure Technologies Inc., a US-based medical device company, acquired Sherlock Biosciences Inc. for an undisclosed amount. Through this acquisition, OraSure intends to broaden its infectious disease testing portfolio by integrating Sherlock’s CRISPR-Cas13 diagnostic platforms and fluorescence-based CRISPR detection technology to advance next-generation molecular diagnostics. Sherlock Biosciences Inc. is a US-based biotechnology company that provides CRISPR-based diagnostic assays utilizing fluorescence detection.

Major companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market are Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Bio‑Rad Laboratories Inc., QIAGEN N.V., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Ginkgo Bioworks, OriGene Technologies Inc., Synthego Corporation, Inscripta Inc., Mammoth Biosciences Inc., Creative Biolabs, Cellecta Inc., GeneCopoeia Inc., SBS Genetech Co. Ltd., Addgene, CrisprBits Private Limited.

North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market includes revenues earned by entities providing services such as pathogen detection, genetic mutation screening, and gene expression analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market includes sales of CRISPR-based detection kits, reagents, Cas enzymes, fluorescent reporters, and assay consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays are molecular diagnostic tools that combine CRISPR-Cas systems with fluorescent reporters to detect specific DNA or RNA sequences. They facilitate rapid, sensitive, and precise detection of pathogens, genetic mutations, or biomarkers. These assays offer high specificity through CRISPR-guided targeting and real-time visualization via fluorescence signals.

The prominent product types of clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays include kits, reagents, instruments, and other variants. Kits are ready-to-use assemblies containing all necessary materials for CRISPR-based fluorescence detection experiments. They include Cas9-based, Cas12-based, Cas13-based assays, and others, with fluorescence-based and lateral flow detection methods. Applications include gene editing, diagnostics, drug discovery, and others, serving academic and research institutes, pharmaceutical and biotechnology companies, clinical laboratories, and other end-users.

Tariffs on imported CRISPR reagents, fluorescent probes, and molecular biology instruments are impacting the CRISPR fluorescence assay market by increasing costs for kits, reagents, and instruments, particularly affecting Cas12, Cas13, and multiplex assay segments. Regions such as North America, Europe, and Asia-Pacific that rely on imported enzymes and fluorescence readers are most affected. While tariffs elevate costs, they encourage domestic manufacturing, local reagent production, and innovation in cost-effective assay platforms, fostering long-term regional market resilience.

The clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market research report is one of a series of new reports that provides clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market statistics, including clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays industry global market size, regional shares, competitors with a clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market share, detailed clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market segments, market trends and opportunities, and any further data you may need to thrive in the clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays industry. This clustered regularly interspaced short palindromic repeats (CRISPR) fluorescence assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.